Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 1
2008 2
2013 1
2014 4
2015 3
2016 2
2018 4
2019 2
2020 1
2021 2
2023 1
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Results by year

Filters applied: . Clear all
Page 1
Efforts to Develop KRAS Inhibitors.
Holderfield M. Holderfield M. Cold Spring Harb Perspect Med. 2018 Jul 2;8(7):a031864. doi: 10.1101/cshperspect.a031864. Cold Spring Harb Perspect Med. 2018. PMID: 29101115 Free PMC article. Review.
Tumor-selective effects of active RAS inhibition in pancreatic ductal adenocarcinoma.
Wasko UN, Jiang J, Curiel-Garcia A, Wang Y, Lee B, Orlen M, Drizyte-Miller K, Menard M, Dilly J, Sastra SA, Palermo CF, Dalton T, Hasselluhn MC, Decker-Farrell AR, Chang S, Jiang L, Wei X, Yang YC, Helland C, Courtney H, Gindin Y, Zhao R, Kemp SB, Clendenin C, Sor R, Vostrejs W, Amparo AA, Hibshman PS, Rees MG, Ronan MM, Roth JA, Bakir B, Badgley MA, Chabot JA, Kluger MD, Manji GA, Quintana E, Wang Z, Smith JAM, Holderfield M, Wildes D, Aguirre AJ, Der CJ, Vonderheide RH, Stanger BZ, Singh M, Olive KP. Wasko UN, et al. Among authors: holderfield m. bioRxiv [Preprint]. 2023 Dec 4:2023.12.03.569791. doi: 10.1101/2023.12.03.569791. bioRxiv. 2023. PMID: 38105998 Free PMC article. Preprint.
Tumor-selective activity of RAS-GTP inhibition in pancreatic cancer.
Wasko UN, Jiang J, Dalton TC, Curiel-Garcia A, Edwards AC, Wang Y, Lee B, Orlen M, Tian S, Stalnecker CA, Drizyte-Miller K, Menard M, Dilly J, Sastra SA, Palermo CF, Hasselluhn MC, Decker-Farrell AR, Chang S, Jiang L, Wei X, Yang YC, Helland C, Courtney H, Gindin Y, Muonio K, Zhao R, Kemp SB, Clendenin C, Sor R, Vostrejs WP, Hibshman PS, Amparo AM, Hennessey C, Rees MG, Ronan MM, Roth JA, Brodbeck J, Tomassoni L, Bakir B, Socci ND, Herring LE, Barker NK, Wang J, Cleary JM, Wolpin BM, Chabot JA, Kluger MD, Manji GA, Tsai KY, Sekulic M, Lagana SM, Califano A, Quintana E, Wang Z, Smith JAM, Holderfield M, Wildes D, Lowe SW, Badgley MA, Aguirre AJ, Vonderheide RH, Stanger BZ, Baslan T, Der CJ, Singh M, Olive KP. Wasko UN, et al. Among authors: holderfield m. Nature. 2024 Apr 8. doi: 10.1038/s41586-024-07379-z. Online ahead of print. Nature. 2024. PMID: 38588697
Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy.
Holderfield M, Lee BJ, Jiang J, Tomlinson A, Seamon KJ, Mira A, Patrucco E, Goodhart G, Dilly J, Gindin Y, Dinglasan N, Wang Y, Lai LP, Cai S, Jiang L, Nasholm N, Shifrin N, Blaj C, Shah H, Evans JW, Montazer N, Lai O, Shi J, Ahler E, Quintana E, Chang S, Salvador A, Marquez A, Cregg J, Liu Y, Milin A, Chen A, Ziv TB, Parsons D, Knox JE, Klomp JE, Roth J, Rees M, Ronan M, Cuevas-Navarro A, Hu F, Lito P, Santamaria D, Aguirre AJ, Waters AM, Der CJ, Ambrogio C, Wang Z, Gill AL, Koltun ES, Smith JAM, Wildes D, Singh M. Holderfield M, et al. Nature. 2024 Apr 8. doi: 10.1038/s41586-024-07205-6. Online ahead of print. Nature. 2024. PMID: 38589574
Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers.
Jiang J, Jiang L, Maldonato BJ, Wang Y, Holderfield M, Aronchik I, Winters IP, Salman Z, Blaj C, Menard M, Brodbeck J, Chen Z, Wei X, Rosen MJ, Gindin Y, Lee BJ, Evans JW, Chang S, Wang Z, Seamon KJ, Parsons D, Cregg J, Marquez A, Tomlinson ACA, Yano JK, Knox JE, Quintana E, Aguirre AJ, Arbour KC, Reed A, Gustafson WC, Gill AL, Koltun ES, Wildes D, Smith JAM, Wang Z, Singh M. Jiang J, et al. Among authors: holderfield m. Cancer Discov. 2024 Apr 9:OF1-OF24. doi: 10.1158/2159-8290.CD-24-0027. Online ahead of print. Cancer Discov. 2024. PMID: 38593348
KRAS G13D sensitivity to neurofibromin-mediated GTP hydrolysis.
Rabara D, Tran TH, Dharmaiah S, Stephens RM, McCormick F, Simanshu DK, Holderfield M. Rabara D, et al. Among authors: holderfield m. Proc Natl Acad Sci U S A. 2019 Oct 29;116(44):22122-22131. doi: 10.1073/pnas.1908353116. Epub 2019 Oct 14. Proc Natl Acad Sci U S A. 2019. PMID: 31611389 Free PMC article.
RAS signaling: Divide and conquer.
Holderfield M, Morrison DK. Holderfield M, et al. Nat Chem Biol. 2016 Dec 16;13(1):7-8. doi: 10.1038/nchembio.2264. Nat Chem Biol. 2016. PMID: 27984577 Free PMC article.
Sensitivity of Oncogenic KRAS-Expressing Cells to CDK9 Inhibition.
Lai LP, Brel V, Sharma K, Frappier J, Le-Henanf N, Vivet B, Muzet N, Schell E, Morales R, Rooney E, Basse N, Yi M, Lacroix F, Holderfield M, Englaro W, Marcireau C, Debussche L, Nissley DV, McCormick F. Lai LP, et al. Among authors: holderfield m. SLAS Discov. 2021 Aug;26(7):922-932. doi: 10.1177/24725552211008853. Epub 2021 Apr 24. SLAS Discov. 2021. PMID: 33896272 Free PMC article.
26 results